Trial Title:
The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma
NCT ID:
NCT06355427
Condition:
Cholangiocarcinoma
Conditions: Official terms:
Cholangiocarcinoma
Conditions: Keywords:
FAPI
Cholangiocarcinoma
FAPI PET/CT
Fibroblast Activation Protein Inhibitor
Proximal cholangiocarcinoma
FAPIChol
PET/CT
18F-FAPI-74
Study type:
Interventional
Study phase:
Phase 2/Phase 3
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Diagnostic
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
[18F]F-FAPI PET-CT
Description:
[18F]F-FAPI PET-CT in addition to regular CT and MRI, prior to participants undergoing
surgery
Arm group label:
FAPI PET-CT
Summary:
Background
Bile duct cancer (cholangiocarcinoma) represents the second most common type of
hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually.
Currently, surgical resection is the only curative option. However, patients are not
eligible for surgery if the tumor cannot be resected or the cancer has spread. For this
group of patients, palliative chemotherapy is the most suited treatment option. To find
out if a patient is suited for surgery, CT and MRI are performed. These imaging
techniques, however, struggle to correctly identify small cancer spreads that are smaller
than 1 cm. Therefore, cancer that has already spread can be found during surgery. In
these cases, the tumor cannot be removed and the surgery therefore has not been of any
benefit for the patient. These surgeries could be avoided by implementing a diagnostic
tool with significantly higher accuracy than those currently used. Single center studies
have shown that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising
technique for determining metastases in tumors with prominent desmoplastic reactions,
like cholangiocarcinoma. The investigators predict that implementation of preoperative
FAPI PET-CT could prevent futile surgery for at least half of patients in whom
intra-operative metastasized disease is found using the current work-up.
Patient population
Patients ≥18 years with potentially curable proximal cholangiocarcinoma (perihilar,
intrahepatic and gall bladder cholangiocarcinoma) who are planned to undergo surgery
based on imaging using CT thorax/abdomen and MRI of the upper abdomen. Exclusion criteria
are previous abdominal surgery or chemotherapy, known pregnancy or lactation and
indication for FDG PET-CT.
Participation in this study
Participation would mean to undergo FAPI PET-CT prior to the scheduled surgery. This will
take up about half a day of the participant's time. Afterwards, participants receive
questionnaires about quality of life and use of healthcare services over a period of six
months in order for the researchers to be able to calculate the cost-effectiveness of
additional FAPI PET-CT.
Risks and benefits of participation
Patients may benefit directly from [18F]F-FAPI PET-CT by allowing for more targeted
treatment, possibly avoiding futile surgery and receiving chemotherapy or best clinical
support instead, minimizing treatment delay. Avoiding futile surgery will also prevent
patients from being exposed to the risks and discomfort associated with surgery: hospital
stay, possibility of intraoperative or postoperative complications, postoperative pain
and recovery, and mortality.
Potential risks and burdens associated with this study are an extra hospital visit and a
time burden of approximately half a day. Risks associated with administering FAPI are
(re)bleed and infection. Both risks have a minimal probability of onset and can usually
easily be treated. As [18F]F-FAPI is a sub-pharmacologically micro-dosed diagnostic
tracer, the risk of allergic reactions is expected to be minimal and no tissue damage is
expected. The burden associated with undergoing a PET-CT may be laying still for a
certain time, and possible experience of claustrophobia. Possible metastases of the
cancer will have to be confirmed when suspicious findings are seen on FAPI PET-CT. This
could mean that participants will have to undergo additional testing such as imaging (CT
or MRI) or biopsy. Undergoing FAPI PET-CT prior to surgery will result in a surgical
delay when compared with the current clinical practice. The investigators do not expect
this delay to influence the patient's prognosis. Follow-up will result in a time burden
for patients to answer questionnaires on a two-weekly or monthly basis.
Detailed description:
Rationale
Bile duct cancer (cholangiocarcinoma) represents the second most common type of
hepatobiliary cancer worldwide with an incidence of 0.35 to 2 per 100.000 annually.
Currently, surgical resection is the only curative option. However, patients are not
eligible for surgery if vascular invasion, distant tumor positive lymph nodes, peritoneal
metastases or organ metastases are found on preoperative imaging. For this group of
patients, palliative chemotherapy is the most suited treatment option. The preoperative
imaging currently includes CT, MRI and FDG PET-CT. In around 29 % of potentially
resectable tumors (based on preoperative imaging) metastases are found during subsequent
surgery. These explorations could be avoided by implementing a diagnostic tool with
significantly higher accuracy than those currently used. Single center studies have shown
that fibroblast activation protein inhibitor (FAPI) PET-CT is a very promising technique
for determining metastases in tumors with prominent desmoplastic reactions, like
cholangiocarcinoma. Our systematic review has shown it is superior to the commonly used
FDG PET-CT for this indication. The investigators predict that implementation of
preoperative FAPI PET-CT could alter treatment course for at least half (13%) of patients
in whom intra-operative metastasized disease is found using the current work-up.
Objective
The primary aim of this study is to assess whether preoperative [18F]F-FAPI PET-CT in
addition to standard preoperative imaging can successfully identify metastasized disease
and change treatment plan in patients with potentially resectable proximal bile duct
cancer (intrahepatic, perihilar and gall bladder cholangiocarcinoma). This study also
aims to evaluate if adding [18F]F-FAPI PET-CT to preoperative imaging is cost-effective.
Main trial endpoints
The main endpoint is the diagnostic accuracy (sensitivity, specificity, positive
predictive value, negative predictive value) of [18F]F-FAPI PET-CT.
Secondary trial endpoints
- Diagnostic accuracy of [18F]F-FAPI PET-CT per abdominal region and per lesion
- The number of additional significant findings on [18F]F-FAPI PET-CT
- Change of treatment: true change and virtual change
- The number of times readers' conclusions differed and why
- Cost-effectiveness analysis, budget impact analysis (BIA), sector costs, societal
costs, health-related quality of life (HRQoL)
- The number of additional significant findings on [18F]F-FAPI PET-CT
- Number of days between date of first imaging (CT/MRI) and starting date of
chemotherapy, palliative therapy or surgical resection
- The incidence and severity of AEs and SAEs according to CTCAEv5
- VOI, TTP, K1 and k2, SUV and TBR (in a subgroup of patients)
Trial design
Prospective multicenter observational cohort study, expected total duration 4 years.
Participants will be participating for at least six months.
Trial population
Patients ≥18 years with potentially curable proximal cholangiocarcinoma (perihilar,
intrahepatic and gall bladder cholangiocarcinoma) who are planned to undergo surgery
based on imaging using CT thorax/abdomen and MRI of the upper abdomen. Exclusion criteria
are previous abdominal surgery or chemotherapy, known pregnancy or lactation and
indication for FDG PET-CT.
Interventions
If patients are deemed eligible for surgery (laparoscopy or laparotomy) by the weekly
organ-specific multidisciplinary team (MDT) including an abdominal nuclear medicine
specialist, radiologist, surgeon, gastroenterologist/hepatologist, oncologist and,
optionally, pathologist, patients will be asked to participate in the study. After
inclusion, patients will receive additional [18F]F-FAPI PET-CT. Patients who underwent
[18F]F-FAPI PET-CT will undergo follow-up for at least six months, if clinically
advisable. Follow-up includes information regarding additional imaging, surgery or
complications. To determine cost-effectiveness, patients' medical consumption will be
elicited using two questionnaires. Patients will be asked to fill out the 'institute for
Medical Technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ)' at three
and six months after their initial CT/MRI imaging (before [18F]F-FAPI PET-CT or surgery).
Patients will also be asked to fill out the European Organisation for Research and
Treatment of Cancer (EORTC) group's QLQ-C30 and QLQ-BIL21 questionnaires and the EuroQol
(EQ) Group's EQ-5D-5L questionnaire once every two weeks during the first two months
after [18F]F-FAPI PET-CT and then once every four weeks until six months follow-up.
Risks and benefits
Patients may benefit directly from [18F]F-FAPI PET-CT by allowing for more targeted
treatment, possibly avoiding futile surgery and receiving chemotherapy or best clinical
support instead, minimizing treatment delay. Avoiding futile surgery will also prevent
patients from being exposed to the risks and discomfort associated with surgery: hospital
stay, possibility of intraoperative or postoperative complications, postoperative pain
and recovery, and mortality.
Potential risks and burdens associated with this study are an extra site visit and a time
burden of approximately half a day. Risks associated with vena puncture are (re)bleed and
infection. Both risks have a minimal probability of onset, and when anticipated upon, are
not expected to have significant clinical consequences. Risks associated with the
administration of the study agent are allergic reactions and radiation burden.
[18F]F-FAPI is a sub-pharmacologically micro-dosed diagnostic tracer, which is why the
risk of allergic reactions is expected to be minimal and no tissue damage is expected.
The burden associated with undergoing a PET-CT may be laying still for a certain time,
and possible experience of claustrophobia. Metastases will have to be confirmed when
suspicious findings are seen on [18F]F-FAPI PET-CT. This could mean subjects will have to
undergo additional testing such as imaging (CT or MRI) or biopsy. If these additional
tests are negative for metastases, the subject's exploratory surgery will have been
needlessly delayed. Having to undergo [18F]F-FAPI PET-CT prior to surgery will also
result in a surgical delay when compared with the current clinical practice. The
investigators do not expect this delay to influence the subject's prognosis. Follow-up
will result in a time burden for patients to answer questionnaires on a two-weekly or
monthly basis.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Patient is scheduled for explorative laparoscopy or laparotomy for suspicion of
proximal cholangiocarcinoma (perihilar, intrahepatic and gall bladder
cholangiocarcinoma)
- Tumor is regarded as resectable based on preoperative CT and MRI
- Patient is 18 years or older and is able to give informed consent
Exclusion Criteria:
- Previous abdominal surgery or chemotherapy
- Patient had FDG PET-CT in addition to preoperative CT and MRI
- Contra-indication for performing PET-CT
- Indication for FDG PET-CT
- Pregnancy or lactation, for the latter, temporary discontinuation may be considered.
- Known allergic reaction to therapeutic radiopharmaceuticals
- Inability to lie still on the back for the duration of PET-CT
- Impaired renal function, defined as eGFR (MDRD) <25 ml/min/1,73 m2. An exception
can be made in consultation with the treating physician.
- Any (other) condition, disease, metabolic dysfunction, physical examination finding,
or clinical laboratory finding that may affect the interpretation of the results, or
which might contribute substantially to the patient's experience of study burden
(such as non-suppressible claustrophobia)
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
September 1, 2024
Completion date:
February 1, 2028
Lead sponsor:
Agency:
Mara Veenstra, MD
Agency class:
Other
Collaborator:
Agency:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Agency class:
Other
Collaborator:
Agency:
UMC Utrecht
Agency class:
Other
Source:
Erasmus Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06355427
